Abstract: A vaginal contraceptive suppository having both a rapid release of active ingredient and prolonged duration of effectiveness. The suppository comprises a mixture of sodium starch glycolate, a thickening agent and a vegetable oil base combined with a spermicide.

Abstract: Specimen test slides for occult blood having a receiving sheet between a front panel and a rear panel with openings in the front and rear panels and pivotal covers coated with 2,6-di-tert-butyl-p-cresol to cover said openings.

Abstract: Orally administrable pharmaceutical dosage units having a shape such that its most stable position on a horizontal flat surface is tilted. The units may be tablets, capsules, cachets, wafers, lozenges or analogous confections and candies. For the dosage unit to tilt it has a main body which has projections on its surfaces capable of acting as fulcra. Preferably the dosage units are tablets which have dome or pyramidal shaped projections centrally located on its surfaces. The dosage units are prepared according to the standard procedures of the pharmaceutical art. In the case of tablets, the granulation is compressed employing the appropriately shaped punches and dies.

Abstract: An improved specimen test slide having a front panel and a rear panel. The front panel has one or more openings. Sheet means carrying a test reagent underlie each of these openings for reception of a specimen. A hinged cover overlies the openings. The rear panel has flap means opposite said openings which is pivotable to expose the underside of the sheet to permit application of a developing solution. The underside of the sheet which faces the rear panel also has a control area positioned on a portion thereof at some distance from the portions of the sheet underlying the openings of the front panel. The control area contains positive and negative monitors.

Abstract: Method of producing alpha.sub.2 antagonism by administering thiadiazolo- and oxadiazolotetrahydroisoquinoline compounds.

Abstract: Octahydrobenzo[f]quinoline compounds having 7- and 10-substituents are centrally acting alpha.sub.1 agonists.

Abstract: Specimen test slides for occult blood having a receiving sheet between a front panel and a rear panel with openings in the front and rear panels and pivotal covers coated with 2,6-di-tert-butyl-p-cresol to cover said openings.

Abstract: 2-Aminotetralin compounds having 5- and 8- substituents are centrally acting alpha.sub.1 agonists.

Abstract: 3,3'-Bis-Methylene-1,3-benzothiazine compounds are inhibitors of phenylethanolamine N-methyl-transferase.

Abstract: Thiadiazolo- and oxadiazolotetrahydroisoquinoline compounds are inhibitors of phenylethanolamine N-methyltransferase.

Abstract: A gelatin capsule unit dosage form containing triamterene, 2,4,7-triamino-6-phenylpteridine, which results in rapid dissolution of the active ingredient. The dosage form comprises the addition of a combination of a surfactant and a carbonate or bicarbonate salt as diluents.

Abstract: Bis-2N-alkylene tetrahydroisoquinoline compounds are inhibitors of phenylethanolamine N-methyl-transferase.

Abstract: 1,2,3,4-Tetrahydroisoquinoline compounds having 7- and/or 8-sulfur substituents are inhibitors of phenylethanolamine N-methyltransferase.

Abstract: Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase using novel 2,3-dihydro-1H-isoindole compounds having 4- and 5-substituents.

Abstract: Novel cephalosporins having various acyl substituents at the 7-position and a carboxymethylaminoethyl substituted tetrazolylthiomethyl group at the 3-position of the cephem nucleus are prepared. These compounds have antibacterial activity.

Abstract: Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase using substituted carbamimidothioic acid phenylalkyl esters.

Abstract: A novel process for preparing 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline by cyclizing N-acetyl-2,3-dichlorobenzylaminoacetaldehyde dimethyl acetal with a Lewis acid, reducing, and hydrolyzing the resulting acylated isoquinoline is disclosed.